<?xml version="1.0" encoding="UTF-8"?>
<p id="para0039">The authors have received funding from 
 <funding-source id="gs0001">Canadian Institutes of Health Research</funding-source>, 
 <funding-source id="gs0002">University of British Columbia</funding-source>, 
 <funding-source id="gs0003">British Columbia Health Officers Council</funding-source>, 
 <funding-source id="gs0004">Public Health Agency of Canada</funding-source>, 
 <funding-source id="gs0005">Genome Canada</funding-source>, 
 <funding-source id="gs0006">Genome BC</funding-source>, Michael Smith 
 <funding-source id="gs0007">Foundation for Health Research</funding-source>, and BC 
 <funding-source id="gs0008">Centre for Excellence in HIV/AIDS</funding-source>. Besides the BC Centre for Excellence, none of the funding sources were involved in data analysis or interpretation, nor patient recruitment. The collection of data for the Drug Treatment Program is overseen by the BC Centre for Excellence in HIV/AIDS, Providence Health Care, University of British Columbia, and Simon Fraser University representatives. The corresponding author, JBJ, and AM had full access to all data and had final responsibility for the decision to submit for publication.
</p>
